Long-term virological suppression on first-line efavirenz plus tenofovir=emtricitabine/lamivudine for HIV-1

Stirrup Oliver; Sterne Jonathan; Dunn David T.; Grabmeier-Pfistershammer Katharina; Papastamopoulos Vasileios; Vandenhende Marie-Anne; Wit Ferdinand; Porter Kholoud; Gunsenheimer-Bartmeyer Barbara; Jarrin Inma; Garcia Federico; Faetkenheuer Gerd; Obel Niels; Schultze Anna; Antinori Andrea; Ceccherini-Silberstein Francesca; Mussini Cristina; Chene Genevieve; Neesgaard Bastian; Castagna Antonella; Kouyos Roger; De Wit Stephane; Sonnerbor Anders; Sabin Caroline; Merino Dolores; Barger Diana; Phillips Andrew

首页> 外文期刊>AIDS >Long-term virological suppression on first-line efavirenz plus tenofovir=emtricitabine/lamivudine for HIV-1

【24h】

Long-term virological suppression on first-line efavirenz plus tenofovir=emtricitabine/lamivudine for HIV-1

机译：第一线Efavirenz Plus Tenofovir = HIV-1的长期病毒学抑制

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives: Evaluate long-term rates of virological failure and treatment interruption for people living with HIV (PLWHIV) with viral suppression on first-line efavirenz+tenofovir disoproxil fumarate+emtricitabine/lamivudine (EFV+TDF+FTC/3TC), and compare these according to patient characteristics.

机译：目标：评估生病毒学衰竭和治疗中断的长期率，以艾滋病毒（Plwhviv）与一线efaviraz + Tenofovir毒性富马特+ Emtrickabine / Lamivudine（EFV + TDF + FTC / 3TC）进行病毒抑制，并比较这些根据患者的特征。

著录项

来源
《AIDS》 |2019年第4期|共7页
作者
Stirrup Oliver; Sterne Jonathan; Dunn David T.; Grabmeier-Pfistershammer Katharina; Papastamopoulos Vasileios; Vandenhende Marie-Anne; Wit Ferdinand; Porter Kholoud; Gunsenheimer-Bartmeyer Barbara; Jarrin Inma; Garcia Federico; Faetkenheuer Gerd; Obel Niels; Schultze Anna; Antinori Andrea; Ceccherini-Silberstein Francesca; Mussini Cristina; Chene Genevieve; Neesgaard Bastian; Castagna Antonella; Kouyos Roger; De Wit Stephane; Sonnerbor Anders; Sabin Caroline; Merino Dolores; Barger Diana; Phillips Andrew;
展开▼
作者单位

UCL Inst Global Hlth London England;

Univ Bristol Sch Med Populat Hlth Sci Bristol Avon England;

UCL Inst Global Hlth London England;

Med Univ Vienna Vienna Austria;

Evaggelismos Gen Hosp Athens Greece;

Univ Bordeaux INSERM Bordeaux Populat Hlth Res Ctr U1219 Bordeaux France;

Acad Med Ctr Amsterdam Netherlands;

UCL Inst Global Hlth London England;

Robert Koch Inst Berlin Germany;

Inst Salud Carlos III Madrid Spain;

Hosp Univ San Cecilio Chn Microbiol &

Infect Dis Unit Inst Invest Ibs Granada Granada Spain;

Univ Hosp Cologne Cologne Germany;

Copenhagen Univ Hosp Rigshosp Copenhagen Denmark;

UCL London England;

INMI Lazzaro Spallanzani Italy;

Univ Roma Tor Vergata Dept Expt Med &

Surg Rome Italy;

Univ Modena &

Reggio Emilia Univ Hosp Clin Infect Dis Modena Italy;

Univ Bordeaux INSERM Bordeaux Populat Hlth Res Ctr U1219 Bordeaux France;

Univ Copenhagen CHIP Copenhagen Denmark;

Univ Vita Salute San Raffaele Clin Infect Dis Milan Italy;

Univ Zurich Univ Hosp Zurich Div Infect Dis Zurich Switzerland;

St Pierre Univ Hosp Dept Infect Dis Brussels Belgium;

Karolinska Univ Hosp Karolinska Inst Stockholm Sweden;

UCL Inst Global Hlth London England;

Complejo Hosp Huelva Unidad Gest Clin Enfermedades Infecciosas Huelva Spain;

Univ Bordeaux INSERM Bordeaux Populat Hlth Res Ctr U1219 Bordeaux France;

UCL Inst Global Hlth London England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词
antiretroviral therapy; viral failure; viral rebound; viral suppression; virological control;

机译：抗逆转录病毒治疗;病毒失败;病毒反弹;病毒抑制;病毒学控制;

相似文献

外文文献
中文文献
专利

1. Long-term virological suppression on first-line efavirenz plus tenofovir=emtricitabine/lamivudine for HIV-1 [J] . Stirrup Oliver, Sterne Jonathan, Dunn David T., AIDS . 2019,第4期

机译：第一线Efavirenz Plus Tenofovir = HIV-1的长期病毒学抑制
2. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. [J] . Pozniak AL, Gallant JE, DeJesus E, JAIDS: Journal of acquired immune deficiency syndromes . 2006,第5期

机译：抗逆转录病毒初治患者的替诺福韦富马酸替诺福韦酯，恩曲他滨和依非韦伦与固定剂量齐多夫定/拉米夫定和依非韦伦的比较：病毒学，免疫学和形态学变化-96周分析。
3. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naive subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. [J] . Margot NA, Enejosa J, Cheng AK, JAIDS: Journal of acquired immune deficiency syndromes . 2009,第2期

机译：在研究GS-01-934中，与拉米夫定/ zidovudine和efavirenz相比，天真的抗逆转录病毒受试者对恩曲他滨，替诺福韦二吡呋酯富马酸酯和依非韦伦的抗HIV-1药物耐药性的发展，持续了144周。
4. Quantification of Tenofovir and Emtricitabine in human plasma using high throughput LDTD-MS/MS [C] . Jean Lacoursiere, Annie-Claude Bolduc, Alex Birsan, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：使用高吞吐量LDTD-MS / MS定量人类等离子体中的替诺维尔和Emtrickabine
5. Cost effectiveness analysis of abacavir/lamivudine versus tenofovir/emtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients. [D] . Giguere, Pierre. 2010

机译：阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨联合疗法作为高活性抗逆转录病毒疗法治疗未受HIV感染的患者的成本效益分析。
6. Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1 [O] . -1

机译：一线依法韦仑+替诺福韦+恩曲他滨/拉米夫定对HIV-1的长期病毒学抑制
7. Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1 [O] . 2019

机译：第一线Efaviraz + Tenofovir + Emtricitabine / Lamivudine的长期病毒学抑制

Long-term virological suppression on first-line efavirenz plus tenofovir=emtricitabine/lamivudine for HIV-1

摘要

著录项

相似文献

相关主题

期刊订阅